Alzheimers disease in down syndrome: Neurobiology and risk

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 13, Issue 3, 2007, Pages 237-246

  Zigman, Warren B ^a   Lott, Ira T ^b  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Down syndrome; Epidemiology; Neurobiology; Neuropathology; Oxidative stress; Risk factors; SOD 1

Indexed keywords

AMYLOID; COPPER ZINC SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; CONGENITAL HEART DISEASE; DOWN SYNDROME; GENETIC RISK; HUMAN; LEUKEMIA; LIFESPAN; MORTALITY; NEUROBIOLOGY; NEUROIMAGING; OXIDATIVE STRESS; PREMATURE AGING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ADULT; DEMENTIA; FEMALE; METABOLISM; ONSET AGE; PATHOPHYSIOLOGY; PREGNANCY;

ADULT; AGE OF ONSET; AGING, PREMATURE; ALZHEIMER DISEASE; DEMENTIA; DOWN SYNDROME; FEMALE; HUMANS; OXIDATIVE STRESS; PREGNANCY; RISK FACTORS; SUPEROXIDE DISMUTASE;

EID: 35349031679     PISSN: 10804013     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/mrdd.20163     Document Type: Review

References (172)

1. Andersen K, Launer LJ, Dewey ME, et al. 1999. Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM incidence research group. Neurology 53:1992-1997.
2. Assini A, Cammarata S, Vitali A, et al. 2004. Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment. Neurology 63:828-831.
3. Azizeh BY, Head E, Ibrahim MA, et al. 2000. Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs. Exp Neurol 163:111-122.
4. Badwey JA, Curnutte JT, Robinson JM, et al. 1980. Comparative aspects of oxidative metabolism of neutrophils from human blood and guinea pig peritonea: magnitude of the respiratory burst, dependence upon stimulating agents, and localization of the oxidases. J Cell Physiol 105:541-545.
5. Bar-Peled O, Korkotian E, Segal M, et al. 1996. Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons. Proc Natl Acad Sci USA 93:8530-8535.
6. Barnes LL, Wilson RS, Bienias JL, et al. 2005. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 62:685-691.
7. Bittles AH, Bower C, Hussain R, et al. 2007. The four ages of Down syndrome. Eur J Public Health 17:221-225.
8. Bittles AH, Petterson BA, Sullivan SG, et al. 2002. The influence of intellectual disability on life expectancy. J Gerontol A Biol Sci Med Sci 57:M470-M472.
9. Blennow K, Hampel H. 2003. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2:605-613.
10. Brooksbank BW, Balazs R. 1984. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res 318(1):37-44.
11. Brooksbank BW, Martinez M, Balazs R. 1985. Altered composition of polyunsaturated fatty acyl groups in phosphoglycerides of Down's syndrome fetal brain. J Neurochem 44:869-874.
12. Busciglio J, Andersen JK, Schipper HM, et al. 1998. Stress, aging, and neurodegenerative disorders. Molecular mechanisms. Ann NY Acad Sci 851:429-443.
13. Busciglio J, Yankner BA. 1995. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378:776-779.
14. Bush A, Beail N. 2004. Risk factors for dementia in people with down syndrome: issues in assessment and diagnosis. Am J Ment Retard 109:83-97.
15. Capone G, Kim P, Jovanovich S, et al. 2002. Evidence for increased mitochondrial superoxide production in Down syndrome. Life Sci 70:2885-2895.
16. Cataldo AM, Peterhoff CM, Troncoso JC, et al. 2000. Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157:277-286.
17. Cohen D, Eisdorfer C, Leverenz J. 1982. Alzheimer's disease and maternal age. J Am Geriatr Soc 30:656-659.
18. Corder EH, Saunders AM, Strittmatter WJ, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
19. Cosgrave MP, Tyrrell J, McCarron M, et al. 1999. Age at onset of dementia and age of menopause in women with Down's syndrome. J Intellect Disabil Res 43(Part 6):461-465.
20. Crawford DR, Leahy KP, Abramova N, et al. 1997. Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress. Arch Biochem Biophys 342:6-12.
21. Cutler NR. 1986. Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-d-glucose: healthy aging. Alzheimer's disease and Down syndrome. Prog Neuropsychopharmacol Biol Psychiatry 10:309-321.
22. Dani A, Pietrini P, Furey ML, et al. 1996. Brain cognition and metabolism in Down syndrome adults in association with development of dementia. Neuroreport 7:2933-2936.
23. de-Andrade FM, Larrandaburu M, Callegari-Jacques SM, et al. 2000. Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer's disease in a southern Brazilian population. Braz J Med Biol Res 33:529-537.
24. de Haan JB, Cristiano F, Iannello RC, et al. 1995. Cu/Zn-superoxide dismutase and glutathione peroxidase during aging. Biochem Mol Biol Int 35:1281-1297.
25. Deb S, Braganza J, Norton N, et al. 2000. APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. Br J Psychiatry 176:468-472.
26. Del Bo R, Comi GP, Bresolin N, et al. 1997. The apolipoprotein E ε4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. J Neurol Sci 145:87-91.
27. Delacourte A, Defossez A, Ceballos I, et al. 1988. Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease. Neurosci Lett 92:247-253.
28. Devenny DA, Silverman WP, Hill AL, et al. 1996. Normal ageing in adults with Down's syndrome: A longitudinal study. J Intellect Disabil Res 40(Part 3):208-221.
29. Down JLH. 1866. Observations on an ethnic classification of idiots. London Hospital Reports 3:259-262.
30. Dupuy AM, Mas E, Ritchie K, et al. 2001. The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. Gerontology 47:213-218.
31. Edland SD, Rocca WA, Petersen RC, et al. 2002. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester. Minn Arch Neurol 59:1589-1593.
32. Elroy-Stein O, Bernstein Y, Groner Y. 1986. Overproduction of human Cu/Zn-superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. EMBO J 5:615-622.
33. Ermak G, Cheadle C, Becker KG, et al. 2004. DSCR1(Adapt78) modulates expression of SOD1. FASEB J 18:62-69.
34. Evans RM, Emsley CL, Gao S, et al. 2000. Serum cholesterol. APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54:240-242.
35. Farrer LA, Cupples LA, Connor L, et al. 1991. Association of decreased paternal age and late-onset Alzheimer's disease. An example of genetic imprinting? Arch Neurol 48:599-604.
36. Franceschi M, Comola M, Piattoni F, et al. 1990. Prevalence of dementia in adult patients with trisomy 21. Am J Med Genet Suppl 7:306-308.
37. Fraser J, Mitchell A. 1876. Kalmuc idiocy: report of a case with autopsy with notes on sixty-two cases. J Ment Sci 22:169-179.
38. Furuta A, Price DL, Pardo CA, et al. 1995. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 146:357-367.
39. Gage FH, Bjorklund A. 1986. Compensatory collateral sprouting of aminergic systems in the hippocampal formation following partial deafferation. Hippocampus 3:33-63.
40. Geddes JW, Monaghan DT, Cotman CW, et al. 1985. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 230:1179-1181.
41. Gerli G, Zenoni L, Locatelli GF, et al. 1990. Erythrocyte antioxidant system in Down syndrome. Am J Med Genet Suppl 7:272-273.
42. Glasson EJ, Sullivan SG, Hussain R, et al. 2002. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet 62:390-393.
43. Glasson EJ, Sullivan SG, Hussain R, et al. 2003. Comparative survival advantage of males with Down syndrome. Am J Hum Biol 15:192-195.
44. Goldgaber D, Lerman MI, McBride WO, et al. 1987. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease. Down's syndrome and aging. J Neural Transm Suppl 24:23-28.
45. Gornick ME, Eggers PW, Reilly TW et al. 1996. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 335:791-799.
46. Greber-Platzer S, Fleischmann C, Nussbaumer C, et al. 2003. Increased RNA levels of the 25 kDa synaptosomal associated protein in brain samples of adult patients with Down Syndrome. Neurosci Lett 336:77-80.
47. Green RC, Jayakumar P, Benke K, et al. 2002. Statin use is associated with reduced risk of Alzheimer's disease. Neurobiol Aging 23:S273-S274.
48. Haier RJ, Alkire MT, White NS, et al. 2003. Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology 61:1673-1679.
49. Haier RJ, Jung RE, Yeo RA, et al. 2005. The neuroanatomy of general intelligence: sex matters. Neuroimage 25:320-327.
50. Harper S, Lynch J, Burris S, et al. 2007. Trends in the black-white life expectancy gap in the United States, 1983-2003. JAMA 297:1224-1232.
51. Head E, Lott IT, Hof PR, et al. 2003. Parallel compensatory and pathological events associated with τ pathology in middle aged individuals with Down syndrome. J Neuropathol Exp Neurol 62:917-926.
52. Head E, Lott IT, Patterson D, et al. 2007. Possible compensatory events in adult down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J Alzheimers Dis 11:61-76.
53. Hebert LE, Scherr PA, McCann JJ, et al. 2001. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol 153:132-136.
54. Henderson VW. 2006. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 138:1031-1039.
55. Heun R, Kolsch H, Jessen F. 2006. Risk factors and early signs of Alzheimer's disease in a family study sample. Risk of AD. Eur Arch Psychiatry Clin Neurosci 256:28-36.
56. Heyman A, Wilkinson WE, Hurwitz BJ, et al. 1983. Alzheimer's disease: genetic aspects and associated clinical disorders. Ann Neurol 14:507-515.
57. Holland AJ, Hon J, Huppert FA, et al. 1998. Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br J Psychiatry 172:493-498.
58. Holland AJ, Hon J, Huppert FA, et al. 2000. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J Intellect Disabil Res 44(Part 2):138-146.
59. Hoshino T, Kamino K, Matsumoto M. 2002. Gene dose effect of the APOE-ε4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol Aging 23:41-45.
60. Hoskin EK, Tang MX, Manly JJ, et al. 2004. Elevated sex-hormone binding globulin in elderly women with Alzheimer's disease. Neurobiol Aging 25:141-147.
61. Hyman BT, West HL, Rebeck GW, et al. 1995. Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol 52:373-378.
62. Isbir T, Agachan B, Yilmaz H, et al. 2001. Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer's disease. Am J Alzheimers Dis Other Demen 16:77-81.
63. Janicki MP, Dalton AJ. 2000. Prevalence of dementia and impact on intellectual disability services. Ment Retard 38:276-288.
64. Jenkins EC, Velinov MT, Ye L, et al. 2006. Telomere shortening in T lymphocytes of older individuals with Down syndrome and dementia. Neurobiol Aging 27:941-945.
65. Jervis GA. 1948. Early senile dementia in mongoloid idiocy. Am J Psychiatry 105:102-106.
66. Jick H, Zornberg GL, Jick SS, et al. 2000. Statins and the risk of dementia. Lancet 356:1627-1631.
67. Johannsen P, Christensen JE, Mai J. 1996. The prevalence of dementia in Down syndrome. Dementia 7:221-225.
68. Jorm A. 1996. The epidemiology of Alzheimer's disease. In: The First Shizuoka Forum on Health and Longevity. Mishima City, Japan.
69. Katzman R, Aronson M, Fuld P, et al. 1989. Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol 25:317-324.
70. Khoury MJ, Beaty TH, Cohen BH. 1993. Fundamentals of genetic epidemiology. New York: Oxford University Press. 383 p.
71. Kivipelto M, Helkala EL, Laakso MP et al. 2001. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322:1447-1451.
72. Korenberg JR, Kawashima H, Pulst SM, et al. 1990. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am J Hum Genet 47:236-246.
73. Kowald A, Klipp E. 2004. Alternative pathways might mediate toxicity of high concentrations of superoxide dismutase. Ann NY Acad Sci 1019:370-374.
74. Lai F, Kammann E, Rebeck GW, et al. 1999. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 53:331-336.
75. Lai F, Williams RS. 1989. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 46:849-853.
76. Lambert JC, Mann D, Goumidi L, et al. 2001. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet 357(9256):608-609.
77. Landesman-Dwyer S. 1981. Living in the community. Am J Ment Defic 86:223-234.
78. Launer LJ, White LR, Petrovitch H, et al. 2001. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57:1447-1452.
79. Lejeune J, Gautier M, Turpin R. 1959a. Study of somatic chromosomes from 9 mongoloid children. CR Hebd Seances Acad Sci 248:1721-1722.
80. Lejeune J, Gautier M, Turpin R. 1959b. A study of somatic chromosomes in nine infants with mongolism. CR Acad Sci (Paris) 240:1026-1027.
81. Lesko LJ, Atkinson AJ. 2001. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347.
82. Leverenz JB, Raskind MA. 1998. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150:296-304.
83. Lin HY, Michtalik HJ, Zhang S, et al. 2003. Oxidative and calcium stress regulate DSCR1 (Adapt78/MCIP1) protein. Free Radic Biol Med 35:528-539.
84. Lott IT, Head E. 2005. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 26:383-389.
85. Lott IT, Head E, Doran E, et al. 2006. β-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 3:521-528.
86. Macleod K, Leprince D, Stehelin D. 1992. The ets gene family. Trends Biochem Sci 17:251-256.
87. Madan V, Williams J, Lear JT. 2006. Dermatological manifestations of Down's syndrome. Clin Exp Dermatol 31:623-629.
88. Malamud N. 1972. Neuropathology of organic brain syndromes associated with aging. In: Gaitz CM, editor. Aging Brain. New York: Plenum. p 63-87.
89. Manly JJ, Schupf N, Tang MX, et al. 2005. Cognitive decline and literacy among ethnically diverse elders. J Geriatr Psychiatry Neurol 18:213-217.
90. Mann DM, Yates PO, Marcyniuk B, et al. 1986. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol 12:447-457.
91. Masaki M, Higurashi M, Iijima K, et al. 1981. Mortality and survival for Down syndrome in Japan. Am J Hum Genet 33:629-639.
92. Mausner JS, Kramer S. 1985. Mausner and Bahn epidemiology: an introductory text. Philadelphia, PA: WB. Saunders
93. Mayeux R, Honig LS, Tang MX, et al. 2003. Plasma A[β]40 and A[β]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61:1185-1190.
94. Mayeux R, Stern Y, Ottman R, et al. 1993. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol 34:752-754.
95. Miniño A, Heron M, Smith B. 2006. Deaths: preliminary data for 2004. NCHS Health E-Stats: Hyattsville, MD.
96. Morbidity and Mortality Weekly Report. 2006. Improved national prevalence estimates for 18 selected major birth defects - United States, 1999-2001. In: Control CD, editor, p. 1301-1305.
97. Naslund J, Haroutunian V, Mohs R, et al. 2000. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283:1571-1577.
98. Nelson LD, Orme D, Osann K, et al. 2001. Neurological changes and emotional functioning in adults with Down Syndrome. J Intellect Disabil Res 45(Part 5):450-456.
99. Newberger DS. 2000. Down syndrome: prenatal risk assessment and diagnosis. Am Fam Physician 62:825-832, 837-828.
100. Nistor M, Don M, Parekh M, et al. 2007. α- and β-secretase activity as a function of age and β-amyloid in Down syndrome and normal brain. Neurobiol Aging 28:1493-1506.
101. Norris KH, Hornsby PJ. 1990. Cytotoxic effects of expression of human superoxide dismutase in bovine adrenocortical cells. Mutat Res 237:95-106.
102. Ohara S, Tsukada M, Ikeda S. 1999. On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome. Acta Neuropathol (Berl) 97:85-90.
103. Oliver C, Crayton L, Holland A, et al. 1998. A four year prospective study of age-related cognitive change in adults with Down's syndrome. Psychol Med 28:1365-1377.
104. Oyama F, Cairns NJ, Shimada H, et al. 1994. Down's syndrome: up-regulation of β-amyloid protein precursor and τ mRNAs and their defective coordination. J Neurochem 62:1062-1066.
105. Panossian LA, Porter VR, Valenzuela HF, et al. 2003. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 24:77-84.
106. Patel BN, Pang D, Stern Y, et al. 2004. Obesity enhances verbal memory in postmenopausal women with Down syndrome. Neurobiol Aging 25:159-166.
107. Penrose LS. 1949. The incidence of Mongolism in the general population. J Ment Sci 95:685-688.
108. Pietrini P, Dani A, Furey ML, et al. 1997. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Am J Psychiatry 154:1063-1069.
109. Polvikoski T, Sulkava R, Haltia M, et al. 1995. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333(19):1242-1247.
110. Prasher VP, Chowdhury TA, Rowe BR, et al. 1997. ApoE genotype and Alzheimer's disease in adults with Down syndrome: meta-analysis. Am J Ment Retard 102:103-110.
111. Prasher VP, Chung MC. 1996. Causes of age-related decline in adaptive behavior of adults with Down syndrome: differential diagnoses of dementia. Am J Ment Retard 101:175-183.
112. Prasher VP, Farrer MJ, Kessling AM, et al. 1998. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43:380-383.
113. Reynolds GP, Cutts AJ. 1993. Free radical damage in Down's syndrome brain. Biochem Soc Trans 21:221S.
114. Riley KP, Snowdon DA, Desrosiers MF, et al. 2005. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging 26:341-347.
115. Robakis NK, Wisniewski HM, Jenkins EC, et al. 1987. Chromosome 21q21 sublocalisation of gene encoding β-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1:384-385.
116. Rocca WA. 1987. The etiology of Alzheimer's disease: epidemiologic contributions with emphasis on the genetic hypothesis. J Neural Transm Suppl 24:3-12.
117. Roe CM, Xiong C, Miller JP, et al. 2007. Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 68:223-228.
118. Roizen NJ. 1997. Down syndrome. In: Batshaw ML, editor. Children with disabilities, 4th ed. Baltimore: Brookes. p 361-376.
119. Romas SN, Tang MX, Berglund L, et al. 1999. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53:517-521.
120. Rovelet-Lecrux A, Hannequin D, Raux G, et al. 2006. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24-26.
121. Royston MC, Mann D, Pickering-Brown S, et al. 1994. Apolipoprotein E ε 2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport 5:2583-2585.
122. Rubinsztein DC, Hon J, Stevens F, et al. 1999. Apo E genotypes and risk of dementia in Down syndrome. Am J Med Genet 88:344-347.
123. Saunders AM, Strittmatter WJ, Schmechel D, et al. 1993. Association of apolipoprotein E allele ε 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472.
124. Schapiro MB, Ball MJ, Grady CL, et al. 1988. Dementia in Down's syndrome: cerebral glucose utilization, neuropsychological assessment, and neuropathology. Neurology 38:938-942.
125. Schapiro MB, Grady CL, Kumar A, et al. 1990. Regional cerebral glucose metabolism is normal in young adults with Down syndrome. J Cereb Blood Flow Metab 10:199-206.
126. Schoenberg BS. 1986. Epidemiology of dementia. Neurol Clin 4:447-457.
127. Schupf N. 2002. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 180:405-410.
128. Schupf N, Kapell D, Lee JH, et al. 1994. Increased risk of Alzheimer's disease in mothers of adults with Down's syndrome. Lancet 344:353-356.
129. Schupf N, Kapell D, Lee JH, et al. 1996. Onset of dementia is associated with apolipoprotein E ε4 in Down's syndrome. Ann Neurol 40:799-801.
130. Schupf N, Kapell D, Nightingale B, et al. 1998. Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology 50:991-995.
131. Schupf N, Pang D, Patel BN, et al. 2003. Onset of dementia is associated with age at menopause in women with Down's syndrome. Ann Neurol 54:433-438.
132. Schupf N, Patel, B, Pang, D, et al. 2007. Elevated plasma amyloid β-peptide Aβ42, incident dementia and mortality in Down syndrome. Arch Neurol 64:1007-1013.
133. Schupf N, Patel B, Silverman W, et al. 2001. Elevated plasma amyloid β-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301:199-203.
134. Schupf N, Winsten S, Patel B, et al. 2006. Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome. Neurosci Lett 406:298-302.
135. Schupf N, Zigman W, Kapell D, et al. 1997. Early menopause in women with Down's syndrome. J Intellect Disabil Res 41(Part 3):264-267.
136. Schwartz M, Duara R, Haxby J, et al. 1983. Down's syndrome in adults: brain metabolism. Science 221:781-783.
137. Seltzer GB, Schupf N, Wu HS. 2001. A prospective study of menopause in women with Down's syndrome. J Intellect Disabil Res 45(Part 1):1-7.
138. Shumaker SA, Legault C, Kuller L, et al. 2004. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291:2947-2958.
139. Silverman W, Schupf N, Zigman W, et al. 2004. Dementia in adults with mental retardation: assessment at a single point in time. Am J Ment Retard 109:111-125.
140. Silverman W, Zigman W, Kim H, et al. 1998. Aging and dementia among adults with mental retardation and Down syndrome. Topics Geriatric Rehabil 13:49-64.
141. Smith MA, Perry G, Richey PL, et al. 1996. Oxidative damage in Alzheimer's. Nature 382:120-121.
142. Snowdon DA, Kemper SJ, Mortimer JA, et al. 1996. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275:528-532.
143. Sohn YK, Ganju N, Bloch KD, et al. 1999. Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases. J Neurol Sci 162:133-151.
144. Stern Y. 2006. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 20:112-117.
145. Struwe F. 1929. Histopathologische Untersuchungen über Entstehung und Wesen der senilen Plaques. Z Ges Neurol Psychiatr 122:291-307.
146. Subba Rao K. 2007. Mechanisms of disease: DNA repair defects and neurological disease. Nature Clin Practice 3:162-172.
147. Tang MX, Jacobs D, Stern Y, et al. 1996. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429-432.
148. Tanzi RE, Gusella JF, Watkins PC, et al. 1987. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235:880-884.
149. Teipel SJ, Hampel H. 2006. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet 36:405-415.
150. van Oijen M, Hofman A, Soares HD, et al. 2006. Plasma Aβ(1-40) and Aβ(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5:655-660.
151. van Schrojenstein Lantman-de Valk HM, Haveman MJ, Crebolder HF. 1996. Comorbidity in people with Down's syndrome: a criteria-based analysis. J Intellect Disabil Res 40(Part 5):385-399.
152. Victor M, Ropper AH. 2001. Adams and Victor's principles of neurology. New York: McGraw-Hill. 1692 p.
153. Walsh DM, Klyubin I, Fadeeva JV, et al. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
154. Wasylyk B, Hahn SL, Giovane A. 1993. The Ets family of transcription factors. Eur J Biochem 211:7-18.
155. Wehr H, Parnowski T, Puzynski S, et al. 2000. Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement Geriatr Cogn Disord 11:70-73.
156. Whalley LJ, Starr JM, Athawes R, et al. 2000. Childhood mental ability and dementia. Neurology 55:1455-1459.
157. Wisniewski HM, Rabe A. 1986. Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome. Ann NY Acad Sci 477: 247-260.
158. Wisniewski KE, Wisniewski HM, Wen GY. 1985. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17:278-282.
159. Wolozin B, Scicutella A, Davies P. 1988. Reexpression of a developmentally regulated antigen in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 85:6202-6206.
160. Yafife K, Lui LY, Grady D, et al. 2000. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet 356:708-712.
161. Yang Q, Rasmussen SA, Friedman JM. 2002. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359:1019-1025.
162. Yarom R, Sherman Y, Sagher U, et al. 1987. Elevated concentrations of elements and abnormalities of neuromuscular junctions in tongue muscles of Down's syndrome. J Neurol Sci 79:315-326.
163. Yip AG, Brayne C, Matthews FE. 2006. Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. Age Ageing 35:154-160.
164. Zigman W Jenkins E, Mehta P, et al. 2000. Alzheimer's disease, survival, and genetics in the "oldest old" with Down syndrome. Down syndrome research foundation (Canada)/National Down Syndrome Society (US) new directions in down syndrome research conference, Toronto, Canada.
165. Zigman WB, Jenkins EC, Tycko B, et al. 2005a. Mortality is associated with apolipoprotein E ε4 in nondemented adults with Down syndrome. Neurosci Lett 390:93-97.
166. Zigman W, Schupf N, Haveman M, et al. 1997. The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference. J Intellect Disabil Res 41(Part 1):76-80.
167. Zigman WB, Schupf N, Jenkins EC, et al. 2007. Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome. Neurosci Lett 416:279-284.
168. Zigman WB, Schupf N, Sersen E, et al. 1996a. Prevalence of dementia in adults with and without Down syndrome. Am J Ment Retard 100:403-412.
169. Zigman W, Schupf N, Silverman W 2005b. Cognitive reserve and dementia risk in adults with Down syndrome. 38th Annual Gatlinburg Conference on Research and Theory in Intellectual and Developmental Disabilities, Annapolis, MD.
170. Zigman WB, Schupf N, Urv T, et al. 2002. Incidence and temporal patterns of adaptive behavior change in adults with mental retardation. Am J Ment Retard 107:161-174.
171. Zigman WB, Schupf N, Zigman A, et al. 1993. Aging and Alzheimer disease in people with mental retardation. Int Rev Res Ment Retard 19:41-70.
172. Zigman W, Silverman W, Wisniewski HM. 1996b. Aging and Alzheimer's disease in Down syndrome: clinical and pathological changes. Ment Retard Dev Disabil Res Rev 2:73-79.